GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Second Sight Medical Products Inc (NAS:EYES) » Definitions » Net Current Asset Value

Second Sight Medical Products (Second Sight Medical Products) Net Current Asset Value : $4.17 (As of Jun. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Second Sight Medical Products Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Second Sight Medical Products's net current asset value per share for the quarter that ended in Jun. 2022 was $4.17.

The historical rank and industry rank for Second Sight Medical Products's Net Current Asset Value or its related term are showing as below:

EYES's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.94
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Second Sight Medical Products Net Current Asset Value Historical Data

The historical data trend for Second Sight Medical Products's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Second Sight Medical Products Net Current Asset Value Chart

Second Sight Medical Products Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.73 0.64 0.73 -0.11 5.18

Second Sight Medical Products Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.45 5.27 5.18 4.40 4.17

Competitive Comparison of Second Sight Medical Products's Net Current Asset Value

For the Medical Devices subindustry, Second Sight Medical Products's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Second Sight Medical Products's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Second Sight Medical Products's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Second Sight Medical Products's Price-to-Net-Current-Asset-Value falls into.



Second Sight Medical Products Net Current Asset Value Calculation

Second Sight Medical Products's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2021 is calculated as

Net Current Asset Value Per Share(A: Dec. 2021 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(70.507-2.514-0-0)/13.1364
=5.18

Second Sight Medical Products's Net Current Asset Value (NCAV) per share for the quarter that ended in Jun. 2022 is calculated as

Net Current Asset Value Per Share(Q: Jun. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(57.389-2.591-0-0)/13.1363
=4.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Second Sight Medical Products  (NAS:EYES) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Second Sight Medical Products Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Second Sight Medical Products's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Second Sight Medical Products (Second Sight Medical Products) Business Description

Traded in Other Exchanges
N/A
Address
13170 Telfair Avenue, Sylmar, CA, USA, 91342
Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.
Executives
Lisa Ellen Porter officer: Chief Medical Officer 778 CORDILLERAS AVE, SAN CARLOS CA 94070
Donald Dwyer officer: Chief Business Officer 54 CHERRY FARM LANE, WEST CHESTER PA 19382
Truc Le officer: COO 1905 WEST RED FOX ROAD, SANTA ANA CA 92704
Adam Mendelsohn director, officer: CEO C/O 5858 HORTON ST. SUITE 280, EMERYVILLE CA 94608
Brigid Makes officer: CFO 20245 SW 95TH AVENUE, TUALATIN OR 97062
Gregg Williams director, 10 percent owner PO BOX 200, WALLED LAKE MI 48390-0200
Wilford Dean Baker director 200 FLYNN ROAD, CAMARILLO CA 93012-8790
Larson Alexandra L.p. director 3797 BURNING TREE DRIVE, BLOOMFIELD HILLS MI 48302
Scott Dunbar officer: Acting CEO 13170 TELFAIR AVENUE, SYLMAR CA 91342
Edward Jonathon Sedo officer: Controller 4485 FORESTGLEN CT, MOORPARK CA 93021
Jonathan Will Mcguire director, officer: Chief Executive Officer 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Jessy Dana Dorn officer: VP-Clin & Scientific Affairs 12744 SAN FERNANDO RD. SUITE 400, SYLMAR CA 91342
Edward David Randolph officer: Vice President Manufacturing 12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342
Matthew J Pfeffer director
Aaron Mendelsohn director 224 15TH STREET, SANTA MONICA CA 90402

Second Sight Medical Products (Second Sight Medical Products) Headlines

From GuruFocus

Second Sight Medical Products Announces Closing of Public Offering

By Business Wire Business Wire 06-25-2021

Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)

By Business Wire Business Wire 08-31-2022